Vertex Pharmaceuticals Inc

13 de ago. de 2026, 23:26 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, following a modest decline earlier. The stock remains above its 20-day moving average.

12 de ago. de 2026, 19:42 UTC

Vertex Pharmaceuticals is trading lower today, pulling back from an earlier session high. No specific news has been identified to explain the decline.

11 de ago. de 2026, 19:36 UTC

Vertex Pharmaceuticals gained today after Bank of America Merrill Lynch added it to the US 1 List, reflecting strong confidence in its future prospects.

10 de ago. de 2026, 20:02 UTC

Vertex Pharmaceuticals shares rose following Sionna Therapeutics' trial failure, easing competitive pressure on Trikafta. BMO analyst noted this as a positive for Vertex's franchise.

7 de ago. de 2026, 19:51 UTC

Vertex Pharmaceuticals shares are higher as the Biotechnology sector strengthens. The company reported $3.33 billion in second-quarter revenue, driven by cystic fibrosis sales.

6 de ago. de 2026, 19:26 UTC

Vertex Pharmaceuticals is trading near unchanged levels with no specific news identified. The stock remains within a narrow range today.

5 de ago. de 2026, 19:16 UTC

Vertex Pharmaceuticals shares are higher as Barclays raises its price target to $617. Truist maintains a Buy rating and sets a target of $565.

4 de ago. de 2026, 20:05 UTC

Vertex Pharmaceuticals is rising today, buoyed by analyst upgrades and a strong Q2 revenue of $3.33 billion, with TD Cowen raising its target to $550.

3 de ago. de 2026, 23:26 UTC

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

31 de jul. de 2026, 19:56 UTC

Vertex Pharmaceuticals is trading lower amid broader market trends, despite its $10 billion acquisition of Crinetics Pharmaceuticals still pending closure.

30 de jul. de 2026, 23:26 UTC

Vertex Pharmaceuticals shares are lower in after-market hours, following a notable dip earlier in the session. No specific news was identified to explain the decline.

29 de jul. de 2026, 23:36 UTC

Vertex Pharmaceuticals Inc shares are higher in after-market trading, recovering from an earlier dip. The stock shows notable volatility within its recent trading range.

28 de jul. de 2026, 15:22 UTC

Vertex Pharmaceuticals Inc. shares are higher as biotechnology stocks advance. This follows a recent trend of higher daily closes since Monday's close.

27 de jul. de 2026, 19:51 UTC

Vertex Pharmaceuticals is gaining modestly today amid broader market volatility and a significant decline in crude oil prices affecting overall sentiment.

24 de jul. de 2026, 13:46 UTC

Vertex Pharmaceuticals is experiencing modest gains amid broader market sentiment influenced by a drop in initial jobless claims to a near 54-year low.

22 de jul. de 2026, 20:06 UTC

Vertex Pharmaceuticals is lower amid market volatility and uncertainty ahead of the Federal Reserve meeting, reflecting a cumulative decline since Tuesday's close.

20 de jul. de 2026, 18:41 UTC

Vertex Pharmaceuticals shares are lower amid a broader decline in the Biotechnology sector. The company recently completed a $10 billion acquisition to enhance its portfolio.

17 de jul. de 2026, 18:56 UTC

Vertex Pharmaceuticals shares are declining amid broader market pressures from rising oil prices and inflation concerns linked to military actions in the Gulf region.

16 de jul. de 2026, 19:51 UTC

Biotechnology stocks are advancing, supporting Vertex Pharmaceuticals' upward movement. This marks a shift from the recent trend of higher daily closes.

15 de jul. de 2026, 18:36 UTC

Vertex Pharmaceuticals agrees to acquire Crinetics Pharmaceuticals for $85 per share. Shares are higher as analysts view the deal positively amid easing inflation pressures.

14 de jul. de 2026, 23:16 UTC

Vertex Pharmaceuticals Inc shares are trading lower in after-market hours, continuing a trend of six consecutive daily declines without any specific news to explain the movement.

13 de jul. de 2026, 19:06 UTC

Vertex Pharmaceuticals announced an agreement to acquire Crinetics for $85 per share, valued at $10 billion, while shares are lower during Monday's session.

10 de jul. de 2026, 20:02 UTC

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

9 de jul. de 2026, 23:16 UTC

Vertex Pharmaceuticals shares are lower in after-market trading, with no specific news identified to explain the movement amid broader market sentiment influenced by U.S.-Iran tensions.

8 de jul. de 2026, 23:46 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

7 de jul. de 2026, 19:36 UTC

Vertex Pharmaceuticals shares are lower today following its $10 billion acquisition of Crinetics Pharmaceuticals, despite analyst support and price target increases.

6 de jul. de 2026, 23:02 UTC

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

2 de jul. de 2026, 20:03 UTC

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

1 de jul. de 2026, 20:06 UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

30 de jun. de 2026, 20:07 UTC

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.